Chugai Pharmaceutical Co., Ltd. (4519.T) Stock

Healthcare · Drug Manufacturers - General · Member of Nikkei 225

Chugai Pharmaceutical Co., Ltd. (4519.T) closed at JPY 6,267.00 on 2026-10-15, a change of -5.5 % over the past year, with a market capitalization of JPY 10.54T.

Chugai Pharmaceutical Co., Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Chugai Pharmaceutical Co., Ltd. key figures

Previous close

JPY 6,267.00 (2026-10-15)

1-year change

-5.5 %

Market cap

JPY 10.54T

Enterprise value

JPY 9.35T

P/E ratio (trailing)

22.36

P/E ratio (forward)

27.15

EPS (trailing)

286.42

EPS (forward)

235.91

PEG ratio

1.54

Price to book

5.20

Revenue growth

17.8 %

Earnings growth

19.7 %

Dividend per share (trailing)

138.00

Short ratio

n/a

Employees

5,104

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Chugai Pharmaceutical Co., Ltd. and compare it with other stocks.